People · Operator
Named in public records as an officer, director or promoter · active 2009–2019 · Biotechnology, Other Health Care, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Larimar Therapeutics, Inc. | — | Biotechnology | Series C | $201.0M | $3.3B | 2010 |
| Naurex Inc. | — | Biotechnology | Series C | $156.0M | $3.3B | 2009 |
| Voyager Therapeutics, Inc. | — | Biotechnology | Series C | $119.0M | $215.3M | 2015 |
| Afferent Pharmaceuticals, Inc. | — | Other Health Care | Series C | $58.1M | $1.3B | 2009 |
| Axon Therapies Inc. | — | Other Technology | Series A | $10.8M | $208.0M | 2016 |
| Coridea NC1, Inc. | — | Biotechnology | Series A | $9.0M | $180.8M | 2010 |
| RaNA Therapeutics, Inc. | — | Biotechnology | Seed | $2.7M | $118.3M | 2011 |
Mitchell S. Bloom at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mitchell S. Bloom on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin Starr | 2 | 5 |
| Mark R. Gelfand | 2 | 2 |
| Peter Barrett | 1 | 18 |
| Jean-Francois Formela | 1 | 17 |
| Bruce Booth | 1 | 12 |
| Jonathan Leff | 1 | 11 |
| Mark Levin | 1 | 9 |
| Michael Higgins | 1 | 9 |
| David Neafus | 1 | 7 |
| Mitchell Bloom | 1 | 6 |
| Terry Gould | 1 | 6 |
| Derek Small | 1 | 4 |
| THOMAS HUGHES | 1 | 4 |
| Norbert Riedel | 1 | 4 |
| EDWARD K. CHANDLER | 1 | 3 |
| James A. Geraghty | 1 | 3 |
| Paul S. LaViolette | 1 | 3 |
| Lou Tartaglia | 1 | 3 |
| Neil A. Exter | 1 | 3 |
| James Geraghty | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.